Endologix's AFX2 Bifurcated Endograft System Approved in Australia

 

December 19, 2016—Endologix, Inc. announced that the Australian Therapeutic Goods Administration has approved the AFX2 bifurcated endograft system for endovascular aortic repair (EVAR) of abdominal aortic aneurysms (AAAs). The device will be available for use in Australia beginning in 2017.

According to Endologix, AFX2 reduces procedure steps for the delivery and deployment of the bifurcated endograft. The new device also facilitates percutaneous EVAR by providing the low-profile contralateral access through a 7-F introducer. AFX2 incorporates the company’s ActiveSeal technology and DuraPly expanded polytetrafluoroethylene graft material.

In the company's announcement, Vikram Puttaswamy, MD, commented, “We are pleased with the approval of AFX2 in Australia and look forward to providing this new technology to our patients. AFX2 and its unique ability to preserve the aortic bifurcation represents an important addition to our endovascular AAA treatment options.” Dr. Puttaswamy is a vascular surgeon at Sydney Vascular Surgery in Sydney, Australia.

In February 2016, Endologix announced the commencement of a limited market launch in the United States for AFX2, which was followed by a wide commercial launch in the second quarter. The US Food and Drug Administration approval of the device was announced in October 2015.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.